Evergreen Theragnostics is focused on improving the available options for cancer patients using radiopharmaceuticals. The company is engaged in three core areas: CDMO, Products, and Drug Discovery. Evergreen is headquartered in Springfield, NJ in a state-of-the-art GMP radiopharmaceutical facility. The company was founded in 2019 by a team that brings a strong track record in theragnostic radiopharmaceutical manufacturing and commercialization.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/13/23 | $15,000,000 | Series B | ||
| 04/16/24 | $26,000,000 | Venture |
LIFTT Petrichor Healthcare Capital Management | undisclosed |
